Algerian Minister of Pharmaceutical Industry Ouacim Kouidri held talks with German company Syntegon on October 28, 2026, to finalize negotiations on acquiring a vaccine production line for state-owned Saidal group. The meeting, part of Kouidri's working visit to Germany, was attended by Saidal's Director General and other senior officials. Discussions focused on the project's timeline, industrial capacity, and other related issues.
The acquisition is part of Algerian President Abdelmadjid Tebboune's vision to strengthen national health sovereignty and achieve self-sufficiency in healthcare. The goal is to supply the local market with domestically produced vaccines, following an integrated production process that includes all vaccines on the national vaccination schedule. This initiative aims to reduce reliance on imported vaccines and enhance the country's healthcare capabilities.
Saidal's ambitions extend beyond meeting domestic needs, with plans to export vaccines to African countries through UNICEF's supply programs. This move is expected to increase access to Algerian products in African and international markets. The acquired production line will serve as a foundation for implementing agreements with major international vaccine manufacturers, enabling integrated production and technology transfer to Saidal.
The production line will be equipped with cutting-edge technology and fully automated systems, minimizing human intervention. During his visit, Kouidri toured Syntegon's facilities and witnessed the latest manufacturing equipment. This investment is expected to enhance Saidal's production capabilities and contribute to the country's healthcare development.
Algeria's efforts to boost domestic vaccine production align with global trends, where countries are seeking to enhance their healthcare security and reduce dependence on imports. The acquisition of the German production line is a strategic move to strengthen Saidal's position in the market and increase its export potential. The project is also expected to create new job opportunities and stimulate economic growth.
The successful implementation of this project will depend on various factors, including the timely delivery of the production line, effective technology transfer, and the ability to meet international quality standards. If successful, the initiative could have a positive impact on Algeria's healthcare sector and contribute to the country's economic development.
The Algerian government's commitment to investing in the healthcare sector reflects its recognition of the importance of self-sufficiency in healthcare. The acquisition of the vaccine production line is a significant step towards achieving this goal, and its success will be closely watched by stakeholders in the healthcare industry.
Key points
- Algeria's Saidal group is acquiring a vaccine production line from Germany's Syntegon to boost domestic vaccine production and expand exports to African countries.
